Anniko (penpulimab)

Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.

Patients with a high TLS-to-tumor area ratio exhibited better survival. Our findings lay the groundwork for the feasibility of first-line de-escalated chemotherapy plus anlotinib and penpulimab in metastatic, persistent, or recurrent cervical cancer patients.

P1, N=22, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=34 --> 22 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Nov 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

P2, N=168, Recruiting, Peking University People's Hospital; Peking University People's Hospital

Compared with chemotherapy, except for ipilimumab+chemo [HR = 0.92,95%CI: (0.59-1.40)], atezolizumab+chemo [HR = 0.88, 95%CI: (0.56-1.40)], and durvalumab+chemo [HR = 0.84, 95% CI: (0.52-1.40)], durvalumab+ tremelimumab+chemo [HR = 0...Cemiplimab [HR = 0.48, 95% CI: (0.34-0.67)] showed the best OS benefit...Sugemalimab+chemo provided the best survival benefit [HR = 0.34, 95% CI: (0.24-0.48)]. For PD-L1≥50% tumors, penpulimab showed excellent OS and PFS; for PD-L1 1-49% tumors, pembrolizumab+chemo and camrelizumab+chemo achieved the best OS and PFS, respectively; for PD-L1≥1% tumors, the tislelizumab+chemo and camrelizumab+chemo showed the best OS and PFS results, while for tumors with PD-L1 <1%, both nivolumab and serplulimab+chemo provided significant survival benefit...Ipilimumab+chemo had the highest incidence of adverse events (AEs) &lsqb;OR = 2.0, 95% CI:(1.5-2.7)]. https://www.crd.york.ac.uk/prospero/, identifier CRD420251027447.

P2, N=55, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2023 --> Oct 2025

P1, N=29, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jun 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns

P2, N=90, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P2, N=204, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=10, Not yet recruiting, West China Hospital

P1/2, N=34, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=75 --> 34 | Trial completion date: Dec 2024 --> Mar 2025 | Recruiting --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

This is the first report of neoadjuvant penpulimab in N1/N2 NSCLC, demonstrating efficacy, feasibility, and survival benefits, especially in patients with high tumor mutational burden.